
Quarterly report 2024-Q4
added 01-03-2026
EDAP TMS S.A. EBITDA 2011-2026 | EDAP
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA EDAP TMS S.A.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -18 M | -17.9 M | -2.65 M | 308 K | 2.37 M | 4.08 M | 295 K | -454 K | 1.42 M | 1.49 M | -837 K | -1.58 M | -1.1 M | -1.08 M |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.08 M | -18 M | -2.4 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Abiomed
ABMD
|
254 M | - | - | $ 17.2 B | ||
|
Acutus Medical
AFIB
|
-11.5 M | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
-815 K | - | 3.58 % | $ 2.21 M | ||
|
Apollo Endosurgery
APEN
|
-30.2 M | - | - | $ 475 M | ||
|
Cognyte Software Ltd.
CGNT
|
8.53 M | $ 9.57 | 0.1 % | $ 687 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | - | - | $ 1.77 B | ||
|
Alphatec Holdings
ATEC
|
-57.8 M | $ 22.65 | -0.15 % | $ 3.24 B | ||
|
AxoGen
AXGN
|
3.18 M | $ 33.63 | 0.78 % | $ 1.49 B | ||
|
Axonics Modulation Technologies
AXNX
|
-53.2 M | - | - | $ 3.31 B | ||
|
Apyx Medical Corporation
APYX
|
-16.6 M | $ 3.5 | 1.16 % | $ 121 M | ||
|
Electromed
ELMD
|
10.7 M | $ 28.9 | -0.41 % | $ 244 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | - | -5.86 % | $ 30.6 M | ||
|
Bio-Rad Laboratories
BIO
|
421 M | $ 323.76 | 1.47 % | $ 9.13 B | ||
|
BioSig Technologies
BSGM
|
-12.7 M | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
3.87 B | $ 97.6 | -0.79 % | $ 144 B | ||
|
CONMED Corporation
CNMD
|
217 M | $ 43.07 | -2.56 % | $ 1.33 B | ||
|
Conformis
CFMS
|
-42.2 M | - | - | $ 16.4 M | ||
|
Bruker Corporation
BRKR
|
437 M | $ 54.12 | 3.12 % | $ 8.06 K | ||
|
Abbott Laboratories
ABT
|
8.16 B | $ 125.84 | -0.27 % | $ 219 B | ||
|
InMode Ltd.
INMD
|
113 M | $ 14.47 | 1.47 % | $ 1.15 B | ||
|
CryoLife, Inc.
CRY
|
23.2 M | - | -4.14 % | $ 702 M | ||
|
IRIDEX Corporation
IRIX
|
-8.91 M | $ 1.16 | -2.94 % | $ 18.7 M | ||
|
Cardiovascular Systems
CSII
|
-32.1 M | - | 0.15 % | $ 844 M | ||
|
Cutera
CUTR
|
-148 M | - | -10.19 % | $ 1.99 M | ||
|
LENSAR
LNSR
|
-7.7 M | $ 11.6 | -0.6 % | $ 134 M | ||
|
Soliton, Inc.
SOLY
|
-14.1 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
88.4 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-8.53 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
-15.9 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M | ||
|
Dynatronics Corporation
DYNT
|
-1.97 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
-106 M | - | - | $ 10.2 M | ||
|
Orthofix Medical
OFIX
|
-24.6 M | $ 15.77 | -2.65 % | $ 601 M | ||
|
Intersect ENT, Inc.
XENT
|
-64.8 M | - | - | $ 955 M | ||
|
Second Sight Medical Products
EYES
|
-24.3 M | - | -0.97 % | $ 54.4 M | ||
|
GBS
GBS
|
-9.67 M | - | -0.57 % | $ 7.12 M | ||
|
Align Technology
ALGN
|
753 M | $ 172.23 | 0.97 % | $ 12.9 B | ||
|
Accuray Incorporated
ARAY
|
14 M | $ 0.89 | -0.47 % | $ 91.5 M | ||
|
IRadimed Corporation
IRMD
|
22.8 M | $ 98.81 | -1.19 % | $ 1.25 B | ||
|
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | ||
|
ClearPoint Neuro
CLPT
|
-18.8 M | $ 15.06 | -1.63 % | $ 407 M | ||
|
FONAR Corporation
FONR
|
9.84 M | $ 18.56 | 0.02 % | $ 122 M | ||
|
Sintx Technologies
SINT
|
-12.5 M | $ 3.78 | -1.32 % | $ 14.1 M | ||
|
Sensus Healthcare
SRTS
|
8.33 M | $ 4.82 | 8.8 % | $ 78.6 M | ||
|
Globus Medical
GMED
|
420 M | $ 94.0 | -0.66 % | $ 12.8 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
70.8 M | $ 13.69 | -1.23 % | $ 1.05 B | ||
|
Stryker Corporation
SYK
|
5.12 B | $ 369.46 | 0.61 % | $ 141 B |